


Supplementary 1. Number of Patients newly prescribed Medicinal Cannabis as reported by TGA's Authorised Prescriber Scheme.



*Authorised Prescribers – Medical Practitioners approved by a HREC or endorsed by a specialist college to prescribe medicinal cannabis

Source: TGA. Medicinal Cannabis Authorised Prescriber Scheme data. Australian Government Therapeutic Goods Administration (TGA) 2023. Accessed September 07, 2023.

<https://www.tga.gov.au/products/unapproved-therapeutic-goods/medicinal-cannabis-hub/medicinal-cannabis-access-pathways-and-patient-access-data/medicinal-cannabis-authorised-prescriber-scheme-data>

Supplementary 2. PICO framework with keyword elements, inclusion, and exclusion criteria.

		Keyword elements	Inclusion	Exclusion
Population	Countries allowing therapeutic usage of cannabis, prescribed or otherwise**	<ol style="list-style-type: none"> 1. Cannabis and cannabis-based products 2. Medical and therapeutic 	Studies reporting on monitoring of cannabis use as a medicine for aforementioned indications.	Studies reporting on: <ul style="list-style-type: none"> - Monitoring of recreational cannabis use. - Synthetic Cannabinoid Receptor Agonists
Intervention	Systems for monitoring of side effects and adverse events	<ol style="list-style-type: none"> 3. Monitoring systems 4. Side effects and adverse events 	Systems for monitoring of side effects and adverse events mentioned as a core component of the title or abstract.	Small scale surveys as a monitoring system Studies relating to addictive potential of medicinal cannabis Studies focusing on monitoring of adverse effects on social wellbeing (marriage, behaviour, academic achievement)
Comparison	No established monitoring system	N/A	N/A	N/A
Outcome	Integration of formalized monitoring systems into clinical practice (workflow)	<ol style="list-style-type: none"> 5. Pharmacovigilance 	N/A	N/A
Study design	Peer-reviewed systematic reviews, scoping reviews, meta-analyses and narrative reviews, primary papers, grey literature	N/A	Papers published from Jan 2015 until June 2023.	Papers not published in English. Animal studies Poster presentations Letters to the editor

**Usage for the following indications: Chronic pain, cancer pain, epilepsy, neuropathic pain in MS, AIDS wasting syndrome, chemotherapy-induced nausea and vomiting, sleep disorders/insomnia, psychiatric disorders (PTSD, schizophrenia), inflammatory conditions such as rheumatoid arthritis (RA), Tourette's, irritable bowel syndrome (IBS), Parkinson's disease, dystonia, glaucoma, ADHD, autism.

Supplementary 3. Categories of searches in search strategy.

Category 1 - Cannabis, Medical, Monitoring Systems and Side Effects Keyword Elements			
Cannabis search terms	Medical Keyword search terms	Monitoring system search terms	Side Effects and Adverse Events search terms
Cannabi* OR tetrahydrocannabinol OR THC OR delta9* OR nabiximol* OR dronabinol* or Cannabigerol* OR CBG OR CBN OR marijuana OR marihuana.	Therap* OR medic* OR prescrib* OR prescrip* OR treat*	Surveillance OR post marketing, safety, database, registry, registries, OR monitoring	Side effect* OR adverse effect* OR adverse outcome* OR adverse event*
Category 2 - Cannabis, Medical, Monitoring Systems and Pharmacovigilance Keyword Elements			
Cannabis search terms	Medical search terms	Monitoring search terms	Pharmacovigilance search terms
Cannabi* OR tetrahydrocannabinol OR THC OR delta9* OR nabiximol* OR dronabinol* or Cannabigerol* OR CBG OR CBN OR marijuana OR marihuana.	Therap* OR medic* OR prescrib* OR prescrip* OR treat*	Surveillance OR post marketing, safety, database, registry, registries, OR monitoring	Pharmacovigilance

Supplementary 4 Full electronic search strategy for OVID-Embase

Category 1 search

1. exp postmarketing surveillance/ or exp drug safety/
2. exp pharmacovigilance/ or exp drug surveillance program/
3. exp drug monitoring/
4. ("surveillance" or "post marketing" or "safety" or "database" or "registry" or "registries" or "monitoring").ti,ab,kf.
5. 1 or 2 or 3 or 4
6. exp medical cannabis/ or exp cannabis derivative/ or exp "Cannabis sativa subsp. indica"/ or exp cannabis-induced psychosis/ or exp "Cannabis (genus)"/ or exp cannabis smoking/ or exp cannabis/ or exp "Cannabis sativa subsp. sativa"/ or exp "cannabis use"/
7. cannabino/ or cannabino derivative/ or exp cannabis/ or exp cannabinoid/ or "cannabis (genus)"/ or cannabis addiction/ or cannabis derivative/
8. ("cannabi*" or "tetrahydrocannabinol" or "THC" or "delta9*" or "nabiximol" or "dronabinol" or "cannabigerol" or "CBG" or "CBN" or "marijuana" or "marihuana").ti,ab,kf.
9. 6 or 7 or 8
10. exp drug therapy/ or exp therapy/
11. ("therap*" or "medic*" or "prescrib*" or "prescrip*" or "treat*").ti,ab,kf.
12. 10 or 11
13. exp side effect/dm, si [Disease Management, Side Effect]
14. exp adverse event/ or exp adverse drug reaction/
15. ("side effect*" or "adverse effect*" or "adverse outcome*" or "adverse event*").ti,ab,kf.
16. 13 or 14 or 15
17. 5 and 9 and 12 and 16
18. limit 17 to yr="2015 - 2023"

Category 2 search

1. exp postmarketing surveillance/ or exp drug safety/
2. exp drug surveillance program/ or exp drug monitoring/
3. ("surveillance" or "post marketing" or "safety" or "database" or "registry" or "registries" or "monitoring").ti,ab,kf.
4. 1 or 2 or 3
5. exp pharmacovigilance/
6. pharmacovigilance.ti,ab,kf.
7. 5 or 6
8. exp medical cannabis/ or exp cannabis derivative/ or exp "Cannabis sativa subsp. indica"/ or exp cannabis-induced psychosis/ or exp "Cannabis (genus)"/ or exp cannabis smoking/ or exp cannabis/ or exp "Cannabis sativa subsp. sativa"/ or exp "cannabis use"/
9. cannabino/ or cannabino derivative/ or exp cannabis/ or exp cannabinoid/ or "cannabis (genus)"/ or cannabis addiction/ or cannabis derivative/
10. ("cannabi*" or "tetrahydrocannabinol" or "THC" or "delta9*" or "nabiximol" or "dronabinol" or "cannabigerol" or "CBG" or "CBN" or "marijuana" or "marihuana").ti,ab,kf.
11. 8 or 9 or 10
12. exp drug therapy/ or exp therapy/
13. ("therap*" or "medic*" or "prescrib*" or "prescrip*" or "treat*").ti,ab,kf.
14. 12 or 13
15. 4 and 7 and 11 and 14
16. limit 15 to yr="2015 - 2023"

Supplementary 6. Differences between databases and registries.

Characteristics	Database	Registry
Purpose	Often designed for multiple uses rather than only monitoring therapeutics	Designed with a specific purpose in mind, such as monitoring of effectiveness or safety
Data structure	Includes various data types, such as patient information, clinical trials data, and pharmacological details	Simpler and designed for a specific aim (i.e tracking patient outcomes over time for a specific condition or treatment)
Flexibility	May offer more flexibility, allowing complex queries that can filter several data types	Limited querying capabilities tailored to the specific data it collects
Ownership	Typically owned and created by the same institution	Owned by a variety of organizations but are often initiated by health agencies, research, or medical organisations
Data Sources	Multi-purpose, and can include both research and clinical data	Sources data directly from clinicians, patients, or specific clinical studies.
Updates	If not designed for real time monitoring, may not be regularly updated	Regularly updated for longitudinal monitoring
Scope	Wider in scope, not limited to a specific therapeutic area or patient population	Narrower in scope, focusing on a specific therapy or patient population.

Supplementary 7. Reporting hierarchy of side effects and adverse events associated with CBM usage

